-
Thematic Analysis
NewGeneric Drugs – Physician Perspective – Thematic Intelligence
Reasons to buy the ‘Generic Drugs – Physician Perspective’ thematic intelligence report: Assess healthcare professionals’ attitudes towards generic drugs prescription. Better understand the barriers to the production and uptake of generic medicines. Capture physicians’ opinions on generics substitution. Better understand patients’ preferences. Assess past and future generics uptake. Gain a better understanding of cost consideration when prescribing drugs. Explore the differences across markets. How is our ‘Generic Drugs – Physician Perspective’ report unique from other reports in the market? This...
-
Product Insights
NewLikelihood of Approval Analysis for Staphylococcal Infections
Overview How likely is it that the drugs in Staphylococcal Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Staphylococcal Infections Overview A staphylococcal infection or staph infection is an infection...
-
Product Insights
NewLikelihood of Approval Analysis for Bone Disorders
Overview How likely is it that the drugs in Bone Disorders will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bone Disorders Overview Bones tend to become weaker or loosen their strength...
-
Product Insights
NewLikelihood of Approval Analysis for Neuropathic Pain (Neuralgia)
Overview How likely is it that the drugs in Neuropathic Pain (Neuralgia) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Neuropathic Pain (Neuralgia) Overview Neuropathic pain, also known as neuralgia, is...
-
Product Insights
NewLikelihood of Approval Analysis for Pleural Effusion
Overview How likely is it that the drugs in Pleural Effusion will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pleural Effusion Overview Pleural Effusion also known as fluid in lungs is...
-
Product Insights
NewLikelihood of Approval Analysis for Papillomaviridae Infections
Overview How likely is it that the drugs in Papillomaviridae Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Papillomaviridae Infections Overview Papillomaviruses are small, non-enveloped, epitheliotropic, double-stranded DNA viruses that...
-
Company Insights
NewSilverchain – Digital Transformation Strategies
Silverchain Digital Transformation Strategies Overview Silverchain leverages a real-time, cloud-based Microsoft platform to consolidate real-time patient care information on a single platform. Cloud, virtual care and telemedicine, connected patients, and mixed reality are among the key technologies under focus for the company. The annual ICT spending of Silverchain was estimated at $9.4 million in 2023. A major share of this spending is earmarked for acquiring software, ICT services, and network and communications from vendors. Silverchain leverages a real-time, cloud-based Microsoft...
-
Company Insights
NewJohn Lewis – Digital Transformation Strategies
John Lewis Digital Transformation Strategies Overview John Lewis has been focusing on using AI, big data, cloud, robotics, contactless retail, innovation, digital twin, gaming, electric vehicles, and e-commerce to digitally transform its operations. The annual ICT spending of John Lewis was estimated at $297.9 million for 2023. A major share of this spending is earmarked for acquiring software, network and communications, and ICT services from vendors. John Lewis, the principal trading subsidiary of John Lewis Partnership Plc, owns and operates...
-
Company Insights
NewNIKE – Digital Transformation Strategies
NIKE Digital Transformation Strategies Overview NIKE has been focusing on using AI, blockchain, NFTs, robotics, metaverse, cryptocurrencies, e-commerce, gaming, and virtual reality to digitally transform its operations. The annual ICT spending of NIKE was estimated at $1.3 billion for 2023. A major share of this spending is earmarked for acquiring software, network and communications, and ICT services from vendors. NIKE designs, develops, markets, and sells athletic footwear, equipment, apparel, accessories, and services. The company sells its products to retail accounts...
-
Company Insights
NewMorgan Stanley – Digital Transformation Strategies
Morgan Stanley Digital Transformation Strategies Overview Morgan Stanley is utilizing AI and machine learning to improve its wealth and asset management operations and other operational processes. AI, big data, cloud, and blockchain are among the key technologies under focus for the company. The annual ICT spending of Morgan Stanley was estimated at $4.6 billion in 2023. A major share of this spending is earmarked for acquiring software, ICT services, and network and communications from vendors. Morgan Stanley is utilizing AI...